HC Wainwright set a $10.00 target price on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) in a report released on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
ZIOP has been the subject of several other reports. Zacks Investment Research lowered shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Thursday, April 6th. ValuEngine upgraded shares of ZIOPHARM Oncology from a sell rating to a hold rating in a research note on Monday, July 17th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $13.17.
ZIOPHARM Oncology (NASDAQ ZIOP) opened at 5.63 on Tuesday. The stock’s 50 day moving average is $5.92 and its 200-day moving average is $6.35. The firm’s market capitalization is $791.76 million. ZIOPHARM Oncology has a one year low of $4.55 and a one year high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The firm’s revenue was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.01) earnings per share. On average, analysts anticipate that ZIOPHARM Oncology will post ($0.54) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/04/ziopharm-oncology-inc-nasdaqziop-pt-set-at-10-00-by-hc-wainwright.html.
Hedge funds have recently added to or reduced their stakes in the stock. Mission Wealth Management LLC purchased a new stake in ZIOPHARM Oncology during the first quarter worth $108,000. Ballentine Partners LLC purchased a new stake in ZIOPHARM Oncology during the second quarter worth $162,000. Highbridge Capital Management LLC purchased a new stake in ZIOPHARM Oncology during the fourth quarter worth $164,000. Old West Investment Management LLC purchased a new stake in ZIOPHARM Oncology during the first quarter worth $205,000. Finally, National Planning Corp raised its stake in ZIOPHARM Oncology by 6.3% in the second quarter. National Planning Corp now owns 33,755 shares of the biotechnology company’s stock worth $208,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 38.07% of the company’s stock.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
